Randomized controlled trial evaluating adeno-MOMP and MOMP DNA vaccines against chlamydophila psittaci challenge in cockatiels (Nymphicus hollandicus)

Chlamydophila psittaci causes severe disease in birds and humans, and important economical losses in the avian companion and poultry industry. Vaccines are the most cost-effective measure to control and help prevent infectious diseases, but to date there is no commercial vaccine available. A randomized clinical trial was conducted to assess the efficacy of two recombinant DNA vaccines against C. psittaci in Cockatiels (Nymphicus hollandicus). The first recombinant DNA vaccine has a gene encoding MOMP and the immunostimulant chitosan (MOMP DNA vaccine). The second recombinant DNA vaccine, contained the gene encoding MOMP that was vectored by a replication defective human adenovirus (adeno-MOMP vaccine). Forty adult cockatiels (Nymphicus hollandicus) were used for this study, and divided into each of the vaccinated groups (n=10), positive control (n=10) and a negative control (n=10). The animals were vaccinated on days 0 and 21 with the corresponding vaccine (DNA MOMP vaccine group, adeno-MOMP vaccine group, negative control group) or placebo (positive control group), and both vaccine groups and the positive control were challenged on day 42 Receiving 0.1 ml of inoculum IN containing approximately 106 C. psittaci live organisms. The negative control group was not challenged with any live organisms. The animals were monitored daily for the presence of rhinitis, conjunctivitis, dyspnea, diarrhea and depression. On days 46, 49, 52, 55, 70 and 82, combined choanal and cloacal swabs were taken and submitted for C. psittaci PCR. The surviving birds were tested on day 82 for antichlamydial antibodies (IFA) and for the presence of C. psittaci (PCR) from whole blood and combined choanal-cloacal swabs, and then humanely euthanized. The birds were submitted for necropsy and examined for the presence of macroscopic lesions on conjunctiva, lungs, airsacs, heart, spleen and liver. Individual samples from each of those tissues were taken for histopathology and pooled samples were submitted for C. psittaci culture. There was a failure to detect antibody response by indirect immunofluorescent assay. The cockatiels developed mild clinical signs and minimal mortality after challenge. The necropsy and histopathologic evaluation of the tissues revealed mild to moderate lesions and no significant difference with positive control. Further studies are needed to evaluate the efficacy of the vaccines

Differential Disease Susceptibilities in Experimentally Reptarenavirus-Infected Boa Constrictors and Ball Pythons.

Inclusion body disease (IBD) is an infectious disease originally described in captive snakes. It has traditionally been diagnosed by the presence of large eosinophilic cytoplasmic inclusions and is associated with neurological, gastrointestinal, and lymphoproliferative disorders. Previously, we identified and established a culture system for a novel lineage of arenaviruses isolated from boa constrictors diagnosed with IBD. Although ample circumstantial evidence suggested that these viruses, now known as reptarenaviruses, cause IBD, there has been no formal demonstration of disease causality since their discovery. We therefore conducted a long-term challenge experiment to test the hypothesis that reptarenaviruses cause IBD. We infected boa constrictors and ball pythons by cardiac injection of purified virus. We monitored the progression of viral growth in tissues, blood, and environmental samples. Infection produced dramatically different disease outcomes in snakes of the two species. Ball pythons infected with Golden Gate virus (GoGV) and with another reptarenavirus displayed severe neurological signs within 2 months, and viral replication was detected only in central nervous system tissues. In contrast, GoGV-infected boa constrictors remained free of clinical signs for 2 years, despite high viral loads and the accumulation of large intracellular inclusions in multiple tissues, including the brain. Inflammation was associated with infection in ball pythons but not in boa constrictors. Thus, reptarenavirus infection produces inclusions and inclusion body disease, although inclusions per se are neither necessarily associated with nor required for disease. Although the natural distribution of reptarenaviruses has yet to be described, the different outcomes of infection may reflect differences in geographical origin.IMPORTANCE New DNA sequencing technologies have made it easier than ever to identify the sequences of microorganisms in diseased tissues, i.e., to identify organisms that appear to cause disease, but to be certain that a candidate pathogen actually causes disease, it is necessary to provide additional evidence of causality. We have done this to demonstrate that reptarenaviruses cause inclusion body disease (IBD), a serious transmissible disease of snakes. We infected boa constrictors and ball pythons with purified reptarenavirus. Ball pythons fell ill within 2 months of infection and displayed signs of neurological disease typical of IBD. In contrast, boa constrictors remained healthy over 2 years, despite high levels of virus throughout their bodies. This difference matches previous reports that pythons are more susceptible to IBD than boas and could reflect the possibility that boas are natural hosts of these viruses in the wild

Post-traumatic ocular lymphoma in three rabbits (Oryctolagus cuniculus)

This report describes post-traumatic ocular lymphoma in 3 companion rabbits; 2 rabbits with unilateral disease and 1 with bilateral disease. Historical findings suggestive of a traumatic event included either external unilateral ocular trauma or bilateral phacoemulsification. Severe corneal changes, presence of an anterior chamber mass(es), low intraocular pressures, and ocular discomfort were noted on ophthalmic examinations. All eyes were treated for variable courses with standard ophthalmic topical medications (antibiotic, anti-inflammatories, and steroid) and systemic anti-inflammatories. Based upon progression of disease, all affected eyes were ultimately enucleated; lenticular capsular rupture and a round cell neoplasm effacing normal structures with variable mitotic indices were noted on histopathology. Neoplastic lymphocytes strongly expressed CD79a via immunohistochemistry and lacked expression for CD3, indicating B lymphocyte lineage and not of T cell lineage. A single animal had evidence of local metastasis to a regional lymph node. Post-traumatic sarcomas have been reported in this species previously, however, these cases are the first reports of this novel round cell variant, named post-traumatic ocular lymphoma due to the B cell lineage confirmed through immunohistochemistry. Clinicians should be aware of this clinical presentation and the possibility of metastasis when evaluating ocular pathology in this species. Copyright 2018 Elsevier Inc. All rights reserved

Knemidocoptic Mange in Wild Golden Eagles, California, USA

During 2012–2013 in California, USA, 3 wild golden eagles were found with severe skin disease; 2 died. The cause was a rare mite, most closely related to Knemidocoptes derooi mites. Cautionary monitoring of eagle populations, habitats, and diseases is warranted

Neurological examination in healthy adult inland bearded dragons (Pogona vitticeps).

ObjectiveTo evaluate neurological tests and expected results in inland bearded dragons (Pogona vitticeps) and generate recommendations for bearded dragon-specific neurological examination.Animals26 healthy adult inland bearded dragons.ProceduresA complete neurological examination utilizing tests described in both mammals and reptiles was performed on each lizard, and test feasibility and outcome were recorded.ResultsTests with poor feasibility included oculocardiac reflex (successfully completed in 62% [16/26] of animals) and voluntary ambulation and swallowing by use of a food item (0% [0/26] of animals). Tests with outcomes considered abnormal in mammals but attributable to normal bearded dragon behavior included head position (head tilt present in 12% [3/26]) and head movement (head bob present in 4% [1/26]). Many tests had absent or inconsistent outcomes, including menace response (present in 19% [5/26]), proprioceptive positioning (present in 4% [1/26] in the thoracic limbs and 0% [0/26] in the pelvic limbs), vent reflex (present in 27% [7/26]), and myotatic reflexes (biceps present in 8% [2/26]; patellar, gastrocnemius, and triceps present in 0% [0/26]). Extensor postural thrust was absent in all successfully tested animals, but a novel reflex termed the caudal thoracic extensor reflex was noted instead in all observed animals (100% [21/21]).Clinical relevanceTests with poor feasibility or inconsistent outcomes should have low priority or be excluded from neurological examinations of inland bearded dragons. Normal behaviors should be considered for head position and movement. A bearded dragon-specific neurological examination protocol derived from these findings is described and recommended in order to decrease stress and improve neurolocalization

Single-Dose Pharmacokinetics of Piperacillin/Tazobactam in Hispaniolan Amazon Parrots ( Amazona ventralis )

To determine the pharmacokinetics of piperacillin/tazobactam in Hispaniolan Amazon parrots ( Amazona ventralis ), 8 healthy adult parrots of both sexes were used in a 2-part study. In a pilot study, piperacillin (87 mg/kg) in combination with tazobactam (11 mg/kg) was administered intramuscularly (IM) to 2 birds, and blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours after administration. Based on the results obtained, a main study was done in which piperacillin/tazobactam was administered at 2 different doses. In 3 birds, the initial dose of piperacillin (87 mg/kg)/tazobactam (11 mg/kg) IM was administered, and in 3 birds, the dose was doubled to piperacillin (174 mg/kg)/tazobactam (22 mg/kg) IM. In all 6 birds, blood samples were obtained at 0, 5, 15, and 30 minutes and at 1, 1.5, 2, 2.5, 3, and 4 hours after administration. Quantification of plasma piperacillin and tazobactam concentrations was determined by validated liquid chromatography-mass spectrometry assay. Pharmacokinetic parameters were determined by noncompartmental analysis. After intramuscular administration, the mean ± standard error values of T1/2 (h) was 0.52 ± 0.05 and 0.32 ± 0.07, Tmax (h) was 0.28 ± 0.09 and 0.25 ± 0.10, Cmax (μg/mL) was 86.34 ± 20.62 and 9.03 ± 2.88, and Cmax/dose was 0.99 ± 0.24 and 0.83 ± 0.26 for piperacillin (87 mg/kg) and tazobactam (11 mg/kg), respectively. When the doses were doubled, the T1/2 (h) was 0.65 ± 0.08 and 0.34 ± 0.02, Tmax (h) was 0.28 ± 0.12 and 0.14 ± 0.06, Cmax (μg/mL) was 233.0 ± 6.08 and 22.13 ± 2.35, and Cmax/dose was 1.34 ± 0.03 and 1.02 ± 0.11 for piperacillin and tazobactam, respectively. Results indicate that piperacillin is rapidly absorbed and reaches high initial concentrations; however, it is also rapidly eliminated in the Hispaniolan Amazon parrot, and tazobactam has similar pharmacokinetics as piperacillin. Administration of piperacillin at 87 mg/kg IM q3-4h is recommended for this species to control infections attributed to susceptible bacteria with a minimum inhibitory concentration of ≤4 μg/mL

Single-Dose Pharmacokinetics of Piperacillin/Tazobactam in Hispaniolan Amazon Parrots ( Amazona ventralis )

To determine the pharmacokinetics of piperacillin/tazobactam in Hispaniolan Amazon parrots ( Amazona ventralis ), 8 healthy adult parrots of both sexes were used in a 2-part study. In a pilot study, piperacillin (87 mg/kg) in combination with tazobactam (11 mg/kg) was administered intramuscularly (IM) to 2 birds, and blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours after administration. Based on the results obtained, a main study was done in which piperacillin/tazobactam was administered at 2 different doses. In 3 birds, the initial dose of piperacillin (87 mg/kg)/tazobactam (11 mg/kg) IM was administered, and in 3 birds, the dose was doubled to piperacillin (174 mg/kg)/tazobactam (22 mg/kg) IM. In all 6 birds, blood samples were obtained at 0, 5, 15, and 30 minutes and at 1, 1.5, 2, 2.5, 3, and 4 hours after administration. Quantification of plasma piperacillin and tazobactam concentrations was determined by validated liquid chromatography-mass spectrometry assay. Pharmacokinetic parameters were determined by noncompartmental analysis. After intramuscular administration, the mean ± standard error values of T1/2 (h) was 0.52 ± 0.05 and 0.32 ± 0.07, Tmax (h) was 0.28 ± 0.09 and 0.25 ± 0.10, Cmax (μg/mL) was 86.34 ± 20.62 and 9.03 ± 2.88, and Cmax/dose was 0.99 ± 0.24 and 0.83 ± 0.26 for piperacillin (87 mg/kg) and tazobactam (11 mg/kg), respectively. When the doses were doubled, the T1/2 (h) was 0.65 ± 0.08 and 0.34 ± 0.02, Tmax (h) was 0.28 ± 0.12 and 0.14 ± 0.06, Cmax (μg/mL) was 233.0 ± 6.08 and 22.13 ± 2.35, and Cmax/dose was 1.34 ± 0.03 and 1.02 ± 0.11 for piperacillin and tazobactam, respectively. Results indicate that piperacillin is rapidly absorbed and reaches high initial concentrations; however, it is also rapidly eliminated in the Hispaniolan Amazon parrot, and tazobactam has similar pharmacokinetics as piperacillin. Administration of piperacillin at 87 mg/kg IM q3-4h is recommended for this species to control infections attributed to susceptible bacteria with a minimum inhibitory concentration of ≤4 μg/mL